The South Region hosts a well-established healthcare ecosystem comprising 79,000 healthcare establishments and 231,000 jobs, representing more than one in ten regional jobs. The region benefits from the Marseille Immunology Biocluster, the Eurobiomed, and one of France’s densest university hospital networks, providing a strong foundation for projects in HealthTech, biomanufacturing, and oncology.
For investors and growing companies, the region represents a sector generating €34 billion in annual revenue. The HealthTech segment alone accounts for 600 establishments and €3 billion in turnover. The region offers access to world-class education and training through institutions such as Aix-Marseille University, its faculties of medicine and pharmacy, as well as a strong research ecosystem supported by INSERM, CNRS, and AP-HM, further strengthened by investments under the France 2030 program.
Success Stories
Success Stories
Frequently asked questions about health investment in the South of France
What are Marseille's strengths for immunology research?
Marseille is home to the Marseille Immunology Biocluster (MIB), funded with €96M through France 2030. The project brings together AP-HM, Aix-Marseille University, CNRS and INSERM, with the goal of creating around forty start-ups and generating several thousand jobs by 2030.
How can I recruit qualified health and life sciences professionals?
The region trains thousands of health students each year. Aix-Marseille University, the Faculty of Medicine and Pharmacy, Polytech Marseille and regional engineering schools feed the talent pool in biomedical research, bioproduction and clinical trials.
Are there grants for bioproduction and medical research projects?
Several funding mechanisms are available: France 2030 (bioclusters, bioproduction), regional calls for projects, support from the Eurobiomed competitiveness cluster, and "turnkey" labelled sites. In 2025, over €140M in public funding was mobilised for HealthTech companies in the Région Sud and Occitanie.
Why choose the South of France over Paris or Lyon for HealthTech?
The Région Sud combines proximity to research sites (Luminy, AP-HM), a dedicated competitiveness cluster (Eurobiomed), access to bioproduction infrastructure (Sartorius, Aubagne) and lower establishment costs compared to Paris. The MIB France 2030 programme further strengthens the region's attractiveness for immunology and biotherapies.
Sources and references
Your Expert
